DataSheet_1_Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis.docx

ObjectivesTo evaluate the clinical curative effects and toxicity of neoadjuvant chemoradiotherapy for resectable gastric cancer compared to those of neoadjuvant chemotherapy.
MethodsA systematic review and meta-analysis of the randomized controlled trials (RCTs) of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy were performed in patients with resectable gastric cancer.
ResultsSeven RCTs were included (601 patients; 302 in the neoadjuvant chemoradiotherapy group and 299 in the neoadjuvant chemotherapy group). The neoadjuvant chemoradiotherapy group had an increased number of patients with a complete response [odds ratio (OR) = 3.79, 95% confidence interval (CI): 1.68–8.54, p = 0.001] and improved objective response rate (OR = 2.78, 95% CI: 1.69–4.57, p < 0.0001), 1-year (OR = 3.51, 95% CI: 1.40–8.81, p = 0.007) and 3-year (OR = 2.14, 95% CI: 1.30–3.50, p = 0.003) survival rates, R0 resection rate (OR = 2.21, 95% CI: 1.39–3.50, p = 0.0008), and complete pathologic response (OR = 4.39, 95% CI: 1.59–12.14, p = 0.004). Regarding the incidence of adverse effects after neoadjuvant therapy, only the occurrence rate of gastrointestinal reaction in the neoadjuvant chemoradiotherapy group was higher than that in the neoadjuvant chemotherapy group (OR = 1.76, 95% CI: 1.09–2.85, p = 0.02), and there was no significant difference in other adverse effects. There was no difference in the incidence of postoperative complications between the two groups.
ConclusionNeoadjuvant chemoradiotherapy for resectable gastric cancer has several advantages in terms of efficacy and safety compared to neoadjuvant chemotherapy. Therefore, neoadjuvant chemoradiotherapy has great potential as an effective therapy for resectable gastric cancers.
Systematic Review Registrationhttps://inplasy.com/inplasy-2022-3-0164, registration number INPLASY202230164.

研究目的：评估可切除胃癌患者接受新辅助放化疗对比新辅助化疗的临床疗效与毒性反应。
研究方法：本研究针对可切除胃癌患者中对比新辅助放化疗与新辅助化疗的随机对照试验（randomized controlled trials, RCTs）开展系统评价与荟萃分析。
研究结果：共纳入7项随机对照试验，涉及601例患者，其中新辅助放化疗组302例，新辅助化疗组299例。新辅助放化疗组的完全缓解患者比例更高[比值比（odds ratio, OR）=3.79，95%置信区间（confidence interval, CI）：1.68~8.54，p=0.001]，客观缓解率亦得到提升（OR=2.78，95%CI：1.69~4.57，p<0.0001），1年生存率（OR=3.51，95%CI：1.40~8.81，p=0.007）与3年生存率（OR=2.14，95%CI：1.30~3.50，p=0.003）、R0切除率（OR=2.21，95%CI：1.39~3.50，p=0.0008）以及病理完全缓解率（OR=4.39，95%CI：1.59~12.14，p=0.004）均优于新辅助化疗组。在新辅助治疗后不良反应发生率方面，仅新辅助放化疗组的胃肠道反应发生率高于新辅助化疗组（OR=1.76，95%CI：1.09~2.85，p=0.02），其余不良反应发生率无显著差异；两组术后并发症发生率无统计学差异。
研究结论：相较于新辅助化疗，可切除胃癌患者的新辅助放化疗在疗效与安全性层面均具备多项优势，因此新辅助放化疗作为可切除胃癌的有效治疗手段具有广阔应用前景。
系统评价注册信息：https://inplasy.com/inplasy-2022-3-0164，注册编号INPLASY202230164。